DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

 

More Magazine Features

The importance of breast MR screening for high-risk patients Experts weigh in on MR's emerging role in breast cancer diagnostics

AI to workflow, breast imaging makes advances A look at the latest innovations reaching the healthcare marketplace

Taking the mystery out of breast density One state at a time, awareness is spreading across the country

The benefits of utilizing teleradiology For some providers, outsourcing image interpretation makes a world of difference

In PET and SPECT, getting more sensitive and working smarter A look at the newest systems on the market

See All Magazine Features  

Molecular Imaging Homepage

ITM enters North American partnerships to establish stable n.c.a.-Lutetium-177 supply Enhance use and supply for targeted radionuclide therapy

Generator production for Tc-99m in Australia suspended following mechanical fault Expected to take weeks to repair

James Allison, Padmanee Sharma and Ramy Ibrahim ImaginAb appoints new members to scientific advisory board

Alliance completes deal for Piramal Imaging Expanding market presence in molecular imaging

Siemens announces first global installation of Biograph Vision PET/CT System yields better temporal resolution and sensitivity than previously reported

New PET tracer could help find cure for Alzheimer's Researchers from Yale show they can measure synaptic density: SNMMI

Spectrum Dynamics launches 12 detector SPECT system The VERITON SPECT system debuted at SNMMI

Cardinal Health showcases first integrated cloud solution for nuclear medicine at SNMMI Nuctrac replaces phone and fax orders

GE launched Syntermed's Emory Cardiac Toolbox at SNMMI Affordable option for users with older SPECT systems

Combined radionuclide therapy and immunotherapy shows promise New research unveiled at SNMMI meeting

Molecular theranostics: prostate cancer and neuroendocrine tumor treatment gets personal

by Lauren Dubinsky , Senior Reporter
From the June 2017 issue of DOTmed HealthCare Business News magazine

The concept of personalized medicine has been influencing patient care since at least the dawn of Western medicine more than 2,000 years ago.

Hippocrates, an early proponent of this concept, is said to have observed, "It's far more important to know what person the disease has than what disease the person has."

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



It was not until the 19th century that developments in chemistry, histochemistry and microscopy enabled scientists to understand the underlying causes of diseases. Those breakthroughs ushered in the innovations of the pharmaceutical and medical device industries of the 20th century and gave rise to genetics, imaging and data mining.

More recently, the ability to sequence the human genome finally put the concept of personalized medicine into practice, making it possible for scientists to develop technology that curates diagnosis and treatment for each individual patient.

Theranostics, a combination of therapy and diagnostics, is a form of personalized medicine. While it usually refers to genome and RNA sequencing, molecular theranostics is a uniquely promising specialty that is gaining momentum.

“Theranostics involving molecular nuclear medicine is a very small field within the whole field of medicine, but I think it has the most interesting, practical applications for theranostics," says Dr. Richard Baum, professor of nuclear medicine and chairman and clinical director of the Theranostics Center for Molecular Imaging and Molecular Radiotherapy at Frankfurt University Hospital in Germany.

Molecular theranostics typically involves a PET/CT exam in combination with a diagnostic radiotracer to determine whether a cancer patient would benefit from a specific therapeutic drug.

The field is not new, but it didn't gain traction until recently. The radiotracer iodine-131 was used in 1941 at the Massachusetts Institute of Technology to treat metastatic thyroid cancer, but it wasn't until 2011 that Frankfurt University Hospital launched the first world congress for molecular theranostics.

To date, the Theranostic World Congress has been held four times. In 2013, it was held in India. In 2015, it took place in the U.S. Last November it was in Australia.

The current gold standard
Most cancer patients are still treated based on their symptoms. The physician makes a diagnosis and then selects the treatment using data from large clinical trials, which predict with some certainty if the patient will respond to the treatment.
  Pages: 1 - 2 - 3 - 4 >>

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2018 DOTmed.com, Inc.
ALL RIGHTS RESERVED